Biovance is developed by Golla Center for Plastic Surgery.

What development phase is Biovance in?

Biovance is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Biovance

Golla Center for Plastic Surgery · FDA-approved active Biologic Quality 0/100

At a glance

Generic name	Biovance
Sponsor	Golla Center for Plastic Surgery
Modality	Biologic
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Postmarket Study to Evaluate Biovance® in Diabetic Foot Ulcers (NA)
Pilot Study to Evaluate Clinical Outcomes With the Use of Biovance Following Keloid Scar Revision Surgery (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Biovance CI brief — competitive landscape report
Biovance updates RSS · CI watch RSS
Golla Center for Plastic Surgery portfolio CI